VACS Polypharmacy Workgroup

Slides:



Advertisements
Similar presentations
Line Efficiency     Percentage Month Today’s Date
Advertisements

Veterans Aging Cohort Study (VACS)
ProjectImpactResourcesDeadlineResourcesDeadline Forecast Plan Time Resources Risk 001xx 002xx 003xx 004xx 005xx 006xx 007xx TotalXX Example 1: Portfolio.
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
Veterans Aging Cohort Study (VACS)
Jan 2016 Solar Lunar Data.
HIV and AIDS management in Italy: critical issues
VACS Pulmonary & Critical Care Core
VACS Cancer Core Robert Dubrow, PhD, MD Founding Director

VACS Physical Function & Disability Working Group
VACS Alcohol and Behavior Change Core
HSR Core Co-Chairs: Emily Wang, MD Kathleen McGinnis, DrPH
Lesson 3: The HCV Care Continuum
Saquinavir + RTV versus Lopinavir-RTV in Treatment-Naïve GEMINI Trial
Janet P. Tate, MPH, ScD Co-Director
Q1 Jan Feb Mar ENTER TEXT HERE Notes
Lesson 4: Preventing HCV Reinfection
VACS Opioids Workgroup
Average Monthly Temperature and Rainfall
Maria Rodriguez-Barradas
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
Les Lang  Gastroenterology  Volume 133, Issue 1, (July 2007)
VACS Endocrine and Bone Workgroup

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?
مقدمه ای بر مهارت های زندگی
2017 Jan Sun Mon Tue Wed Thu Fri Sat
Gantt Chart Enter Year Here Activities Jan Feb Mar Apr May Jun Jul Aug
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Future challenges for clinical care of an ageing population infected with HIV: a modelling study  Dr Mikaela Smit, PhD, Kees Brinkman, MD, Suzanne Geerlings,
Jan Sun Mon Tue Wed Thu Fri Sat
VACS Cardiovascular Disease Core
ئەيدىز كېسىلى (AIDS) مەمەتئىمىن دوكتۇر.
RL Cook, KA McGinnis, DA Fiellin, JH Samet, JL Goulet, S Crystal
Quality of HIV Care and Mortality in HIV-Infected Patients Who Use Drugs and Alcohol PT Korthuis, KL Kraemer, KA McGinnis, M Skanderson, AJ Gordon, AC.
Electricity Cost and Use – FY 2016 and FY 2017
Presenter Disclosure Information
Pneumococcal Polysaccharide (PV) Vaccine Failures among HIV-infected Veterans Compared to Non-HIV-infected controls. Maria C. Rodriguez-Barradas, MD.
Impact of Hepatitis C, HIV, or Both on Survival in Veterans in Care Before and After the Introduction of HAART (1996) SL Fultz, MD, MPH CH Chang, PhD AA.
Amy C. Justice, MD, PhD For the VACS Project Team
Integrating and Prioritizing HIV and “non HIV” Care in the cART Era
Қош келдіңіздер.
Depression Treatment in HIV-infected and Uninfected Veterans: Do Rates Vary by HIV Status? Kristen Sueoka YSM IV.
HIV and Aging: The Importance of a Nuanced Approach
Professor of Medicine and Public Health
Patterns, predictors, and consequences of non-medical use prescription opioids in the Veterans Aging Cohort Study Brandon DL Marshall, PhD Manning Assistant.
Aging and HIV: Key Questions and Unifying Concepts
Shawn L Fultz, MD MPH VACS Scientific Meeting, Feb 2004
VACS Antiviral Workgroup
Jeffrey P. Anderson Combination Antiretroviral Therapy and Hepatic Decompensation in HIV/HCV Coinfected Veterans JEFFREY P. ANDERSON.
Safety Group Program Timeline
VACS Mental Health WG Joseph L. Goulet, PhD, MS Director
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
VACS Scientific Meeting 2016
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
HIV and Aging: The Spectrum of Disease Changes
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
Text for section 1 1 Text for section 2 2 Text for section 3 3
VACS Statins Workgroup
Safety Group Program Timeline
Q1 Q2 Q3 Q4 PRODUCT ROADMAP TITLE Roadmap Tagline MILESTONE MILESTONE
Dolutegravir in PEPFAR
Presentation transcript:

VACS Polypharmacy Workgroup Amy Justice, MD, PhD Co-Director E. Jennifer Edelman, MD Co-Director Members: K Akgun, W Becker, D Fiellin, M Freiberg, CL Gibert, K Gordon, V Lo Re, J Naples, M Skanderson, M Sung, J Tate, S Viswanathan, D Weisberg, M Wolff, J Womack, C Wyatt, New Members: K Niehoff, A Tseng, and S Khoo

VACS Polypharmacy Workgroup 1: Althoff KN et al. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016 Sep;11(5):527-536. 2: Weisberg DF et al. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. J Acquir Immune Defic Syndr. 2015 Jun1;69(2):223-33. 3. Justice AC et al. Should everyone ageing with HIV take a statin? Lancet HIV. 2(2)E36-37 Feb 2015 4: Edelman EJ et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013 Aug;30(8):613-28. Cited: 35 times 5: Greene M et al. Management of human immunodeficiency virus infection in advanced age. JAMA. 2013 Apr 3;309(13):1397-405 Cited: 45 times 6: High KP et al. HIV and aging: state of knowledge and areas of critical need for research. A report to the NIH Office of AIDS Research by the HIV and Aging Working Group. J Acquir Immune Defic Syndr. 2012 Jul 1;60 Suppl 1:S1-18. Cited:129 times

Drug Safety Work in VACS 1: Edelman EJ et al.; VACS Project Team. Acetaminophen receipt among HIV- infected patients with advanced hepatic fibrosis. Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1352-6. 2: Edelman EJ et al.; Vacs Project Team. Patient-reported symptoms on the antiretroviral regimen efavirenz/emtricitabine/ tenofovir. AIDS Patient Care STDS. 2012 Jun;26(6):312-9. 3: Tetrault JM et al.; Veterans Aging Cohort Study Team. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exp Res. 2012 Feb;36(2):318-24. 4: Justice AC et al; Veterans Aging Cohort Study Project Team. Drug toxicity, HIV progression, or comorbidity of aging: does tipranavir use increase the risk of intracranial hemorrhage? Clin Infect Dis. 2008 Nov 1;47(9):1226-30.